# US 2023/0265157 A1 · Mhc multimer expression constructs and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265157 A1
- Document ID: US20230265157A1
- Status: Published application
- Kind: A1
- Application number: 18/012,573
- Filed: 2021-06-23
- Published: 2023-08-24
- Earliest claimed: 2020-06-24
- Assignees: Repertoire Immune Medicines, Inc.
- Applicants: Repertoire Immune Medicines, Inc.
- Inventors: Joanna Swain; Michael Birnbaum
- Web page: https://patentgrep.com/patent/US20230265157A1

## CPC

- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C40B 30/06: by measuring effects on living organisms, tissues or cells
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- C07K 14/36: from Actinomyces; from Streptomyces (G)
- C07K 14/47: from mammals
- C07K 14/4703: {Inhibitors; Suppressors}
- C12N 15/62: DNA sequences coding for fusion proteins
- G01N 33/56972: {White blood cells}
- G01N 33/56977: {HLA or MHC typing}
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/21: containing a His-tag
- C07K 2319/22: containing a Strep-tag
- C07K 2319/43: containing a FLAG-tag
- C07K 2319/50: containing protease site
- C07K 2319/70: containing domain for protein-protein interaction
- C12N 2710/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

MHC multimer expression constructs are provided that contiguously encode an MHC-binding peptide, MHC molecule chains and a multimerization domain in the construct such that expression in a host cell results in production of peptide-loaded MHC (pMHC) multimers by the host cell. The multimers can further comprise oligonucleotide barcodes. Peptide exchange can be performed with a plurality of pMHC multimers to create pMHC multimer libraries. Methods of making and using the pMHC multimers and libraries are also provided. Peptide-loaded MHC Class I and MHC Class II multimers, and libraries thereof, are provided.

## Claims

### Claim 1

A method of producing a Major Histocompatibility Complex (MHC) multimer, the method comprising:
(a) providing an MHC multimer expression construct comprising a nucleic acid encoding (i) an MHC-binding peptide operatively linked to a cleavage site; (ii) a first MHC subunit; (iii) a second MHC subunit; and (iv) a multimerization domain;
(b) introducing the MHC multimer expression construct into a host cell; and
(c) expressing the MHC multimer in the host cell.

### Claim 2 (depends on 1)

The method of claim 1, wherein the first MHC subunit is a beta2-microglobulin chain, the second MHC subunit is an MHC Class I alpha chain and the MHC-binding peptide is an MHC Class I binding peptide.

### Claim 3 (depends on 1)

The method of claim 1, wherein the first MHC subunit is an MHC Class I alpha chain, the second MHC subunit is a beta2-microglobulin chain and the MHC-binding peptide is an MHC Class I binding peptide.

### Claim 4 (depends on 2, 3)

The method of claim 2 or claim 3, wherein the MHC Class I binding peptide is a CMV pp65 peptide comprising the amino acid sequence NLVPMVATV (SEQ ID NO: 4).

### Claim 5 (depends on 2, 3)

The method of claim 2 or claim 3, wherein the MHC Class I binding peptide is a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 204-223 and 267-320.

### Claim 6 (depends on 2, 3, 4, 5)

The method of any one of claims 2-5, wherein the MHC Class I alpha chain is an HLA-A*02:01 polypeptide comprising the amino acid sequence shown in SEQ ID NO: 5 or 321.

### Claim 7 (depends on 2, 3, 4, 5)

The method of any one of claims 2-5, wherein the MHC Class I alpha chain comprises an amino acid sequence shown selected from the group of sequences shown in SEQ ID NOs: 76-141.

### Claim 8 (depends on 2, 3, 4, 5, 6, 7)

The method of any one of claims 2-7, wherein the beta2-microglobulin chain comprises an amino acid sequence shown in SEQ ID NO: 143.

### Claim 9 (depends on 1)

The method of claim 1, wherein the first MHC subunit is an MHC Class II alpha chain, the second MHC subunit is an MHC Class II beta chain and the MHC-binding peptide is an MHC Class II binding peptide.

### Claim 10 (depends on 1)

The method of claim 1, wherein the first MHC subunit is an MHC Class II beta chain, the second MHC subunit is an MHC Class II alpha chain and the MHC-binding peptide is an MHC Class II binding peptide.

### Claim 11 (depends on 9, 10)

The method of claim 9 or claim 10, wherein the MHC Class II binding peptide is a CLIP peptide comprising the amino acid sequence KPVSKMRMATPLLMQA (SEQ ID NO: 224).

### Claim 12 (depends on 9, 10)

The method of claim 9 or claim 10, wherein the MHC Class II alpha chain comprises an amino acid sequence shown selected from the group of sequences shown in SEQ ID NOs: 174, 190, 192, 194 and 196.

### Claim 13 (depends on 9, 10)

The method of claim 9 or claim 10, wherein the MHC Class II beta chain comprises an amino acid sequence shown selected from the group of sequences shown in SEQ ID NOs: 174-189, 191, 193, 195 and 197-203.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1-13, wherein the MHC multimer expression construct encodes a linker between the first MHC subunit and the second MHC subunit.

### Claim 15 (depends on 14)

The method of claim 14, wherein the linker is a (G4S)4 linker.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein the MHC multimer expression construct encodes a linker between (i) the first and second MHC subunits and (ii) the multimerization domain.

### Claim 17 (depends on 16)

The method of claim 16, wherein the linker is a (GS)2AG2SGSG3S linker.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1-17, wherein the cleavage site comprises a Factor Xa cleavage site (SEQ ID NO: 235).

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, wherein the multimerization domain comprises streptavidin.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 1-19, wherein the MHC multimer expression construct further encodes a signal peptide.

### Claim 21 (depends on 20)

The method of claim 20, wherein the signal peptide is an Ig Kappa chain V-III region CLL signal peptide.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 1-21, wherein the MHC multimer expression construct further encodes an expression tag.

### Claim 23 (depends on 22)

The method of claim 22, wherein the expression tag is selected from the group consisting of 6×His tag, FLAG tag, V5 tag, Myc tag, protein C tag and combinations thereof.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1-23, wherein the MHC multimer expression construct comprises a nucleic acid encoding, from 5′ to 3′: an optional signal peptide-an MHC-binding peptide-a cleavage site-a first MHC subunit-a linker-a second MHC subunit-a linker-and a multimerization domain.

### Claim 25 (depends on 24)

The method of claim 24, wherein the MHC multimer expression construct comprises a nucleic acid encoding from 5′ to 3′: a signal peptide-an MHC Class I binding peptide-a Factor Xa cleavage site-beta2-microglobulin-a linker-an MHC Class I alpha chain-a linker-and streptavidin.

### Claim 26 (depends on 25)

The method of claim 25, wherein the MHC multimer expression construct encodes an amino acid sequence shown in SEQ ID NO: 3.

### Claim 27 (depends on 25)

The method of claim 25, wherein the MHC multimer expression construct comprises the nucleotide sequence shown in SEQ ID NO: 1.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 1-27, wherein the MHC multimer further comprises an oligonucleotide barcode.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 1-28, wherein the host cell is a mammalian host cell.

### Claim 30 (depends on 29)

The method of claim 29, wherein the host cell is a human embryonic kidney (HEK) cell line.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1-30, wherein the MHC multimer is secreted from the host cell into cell culture medium.

### Claim 32 (depends on 31)

The method of claim 31, wherein the cell culture medium lacks biotin and the method further comprises incubating the MHC multimer with a biotin-conjugated oligonucleotide barcode.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 1-32, which further comprises incubating the MHC multimer with an agent that cleaves the cleavage site.

### Claim 34 (depends on 33)

The method of claim 33, which further comprises incubating the MHC multimer with at least one MHC-binding rescue peptide such that peptide exchange occurs between the MHC-binding peptide and the MHC-binding rescue peptide.

### Claim 35 (depends on 34)

The method of claim 34, which comprises incubating the MHC multimer with a plurality of MHC-binding rescue peptides thereby to produce a library of peptide-bound MHC multimers.

### Claim 36

An isolated Major Histocompatibility Complex (MHC) multimer expression construct, the construct comprising a nucleic acid encoding (i) an MHC-binding peptide operatively linked to a cleavage site; (ii) a first MHC subunit; (iii) a second MHC subunit; and (iv) a multimerization domain.

### Claim 37 (depends on 36)

The construct of claim 36, wherein the first MHC subunit is a beta2-microglobulin chain, the second MHC subunit is an MHC Class I alpha chain and the MHC-binding peptide is an MHC Class I binding peptide.

### Claim 38 (depends on 36)

The construct of claim 36, wherein the first MHC subunit is an MHC Class I alpha chain, the second MHC subunit is a beta2-microglobulin chain and the MHC-binding peptide is an MHC Class I binding peptide.

### Claim 39 (depends on 37, 38)

The construct of claim 37 or claim 38, wherein the MHC Class I binding peptide is a CMV pp65 peptide comprising the amino acid sequence NLVPMVATV (SEQ ID NO: 4).

### Claim 40 (depends on 37, 38)

The construct of claim 37 or claim 38, wherein the MHC Class I alpha chain is an HLA-A*02:01 polypeptide comprising the amino acid sequence shown in SEQ ID NO: 3.

### Claim 41 (depends on 37, 38)

The construct of claim 37 or claim 38, wherein the MHC Class I alpha chain comprises an amino acid sequence shown selected from the group of sequences shown in SEQ ID NOs: 76-141.

### Claim 42 (depends on 37, 38)

The construct of claim 37 or claim 38, wherein the beta2-microglobulin chain comprises an amino acid sequence shown in SEQ ID NO: 143.

### Claim 43 (depends on 36)

The construct of claim 36, wherein the first MHC subunit is an MHC Class II alpha chain, the second MHC subunit is an MHC Class II beta chain and the MHC-binding peptide is an MHC Class II binding peptide.

### Claim 44 (depends on 36)

The construct of claim 36, wherein the first MHC subunit is an MHC Class II beta chain, the second MHC subunit is an MHC Class II alpha chain and the MHC-binding peptide is an MHC Class II binding peptide.

### Claim 45 (depends on 43, 44)

The construct of claim 43 or claim 44, wherein the MHC Class II binding peptide is a CLIP peptide comprising the amino acid sequence KPVSKMRMATPLLMQA (SEQ ID NO: 224).

### Claim 46 (depends on 43, 44)

The construct of claim 43 or claim 44, wherein the MHC Class II alpha chain comprises an amino acid sequence shown selected from the group of sequences shown in SEQ ID NOs: 174, 190, 192, 194 and 196.

### Claim 47 (depends on 43, 44)

The construct of claim 43 or claim 44, wherein the MHC Class II beta chain comprises an amino acid sequence shown selected from the group of sequences shown in SEQ ID NOs: 174-189, 191, 193, 195 and 197-203.

### Claim 48 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The construct of any one of claims 36-47, wherein the MHC multimer expression construct encodes a linker between the first MHC subunit and the second MHC subunit.

### Claim 49 (depends on 48)

The construct of claim 48, wherein the linker is a (G4S)4 linker.

### Claim 50 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The construct of any one of claims 36-49, wherein the MHC multimer expression construct encodes a linker between (i) the first and second MHC subunits and (ii) the multimerization domain.

### Claim 51 (depends on 50)

The construct of claim 50, wherein the linker is a (GS)2AG2SGSG3S linker.

### Claim 52 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The construct of any one of claims 36-51, wherein the cleavage site comprises a Factor Xa cleavage site (SEQ ID NO: 235).

### Claim 53 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The construct of any one of claims 36-52, wherein the multimerization domain comprises streptavidin.

### Claim 54 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The construct of any one of claims 36-53, wherein the MHC multimer expression construct further encodes a signal peptide.

### Claim 55 (depends on 54)

The construct of claim 54, wherein the signal peptide is an Ig Kappa chain V-III region CLL signal peptide.

### Claim 56 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The construct of any one of claims 36-55, wherein the MHC multimer expression construct further encodes an expression tag.

### Claim 57 (depends on 56)

The construct of claim 56, wherein the expression tag is selected from the group consisting of 6×His tag, FLAG tag, V5 tag, Myc tag, protein C tag and combinations thereof.

### Claim 58 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The construct of any one of claims 36-57, wherein the MHC multimer expression construct comprises a nucleic acid encoding, from 5′ to 3′: an optional signal peptide-an MHC-binding peptide-a cleavage site-a first MHC subunit-a linker-a second MHC subunit-a linker-and a multimerization domain.

### Claim 59 (depends on 58)

The construct of claim 58, wherein the MHC multimer expression construct comprises a nucleic acid encoding from 5′ to 3′: a signal peptide-an MHC Class I binding peptide-a Factor Xa cleavage site-beta2-microglobulin-a linker-an MHC Class I alpha chain-a linker-and streptavidin.

### Claim 60 (depends on 59)

The construct of claim 59, wherein the MHC multimer expression construct encodes an amino acid sequence shown in SEQ ID NO: 3.

### Claim 61 (depends on 59)

The construct of claim 59, wherein the MHC multimer expression construct comprises the nucleotide sequence shown in SEQ ID NO: 1.

### Claim 62 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The construct of any one of claims 36-61, which is a plasmid.

### Claim 63 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

A host cell transfected with the construct of any one of claims 36-62.

### Claim 64 (depends on 63)

The host cell of claim 63, which is a mammalian host cell.

### Claim 65 (depends on 64)

The host cell of claim 64, which is a human embryonic kidney (HEK) cell line.

### Claim 66 (depends on 63, 64, 65)

An isolated supernatant comprising a recombinant MHC multimer, wherein the supernatant is isolated from culture medium of the host cell of any one of claims 63-65.

### Claim 67 (depends on 66)

The supernatant of claim 66, wherein the culture medium lacks biotin and the supernatant further comprises a biotin-conjugated oligonucleotide barcode.

### Claim 68 (depends on 66, 67)

The supernatant of claim 66 or claim 67, wherein the supernatant further comprises an agent that cleaves the cleavage site.

### Claim 69 (depends on 68)

The supernatant of claim 68, which further comprises at least one MHC-binding rescue peptide such that peptide exchange occurs between the MHC-binding peptide and the MHC-binding rescue peptide.

### Claim 70 (depends on 69)

The supernatant of claim 69, which comprises a plurality of MHC-binding rescue peptides such that following peptide exchange a library of peptide-bound MHC multimers is contained in the supernatant.

### Claim 71 (depends on 35)

A polypeptide library comprising a plurality of peptide loaded MHC (pMHC) multimers, wherein each of the pMHC multimers comprises two or more pMHC monomers conjugated to a multimerization domain, wherein the polypeptide library is prepared according to the method of claim 35.

### Claim 72 (depends on 71)

The polypeptide library of claim 71, which comprises pMHCI multimers.

### Claim 73 (depends on 71)

The polypeptide library of claim 71, which comprises pMHCII multimers.

### Claim 74 (depends on 71)

A method of isolating pMHC-multimer bound lymphocytes comprising:
(a) contacting a plurality of lymphocytes with the library of pMHC multimers of claim 71, thereby to produce a corresponding plurality of lymphocytes each bound to a pMHC-multimer; and
(b) isolating a pMHC-multimer bound lymphocyte.

### Claim 75 (depends on 71)

A method of identifying a lymphocyte bound to an pMHC multimer comprising:
(a) contacting a plurality of lymphocytes with the library of pMHC multimers of claim 71;
(b) compartmentalizing a lymphocyte of the plurality of lymphocytes bound to a pMHC multimer of the library in a single compartment, wherein the pMHC multimer comprises a unique identifier; and
(c) determining the unique identifier for the pMHC bound to the compartmentalized lymphocyte.

### Claim 76 (depends on 74, 75)

The method of claim 74 or claim 75, wherein the pMHC multimers are pMHCI multimers.

### Claim 77 (depends on 74, 75)

The method of claim 74 or claim 75, wherein the pMHC multimers are pMHCII multimers.

### Claim 78 (depends on 74, 75, 76, 77)

The method of any one of claims 74-77, wherein the lymphocyte is a T cell, B cell, or NK cell.
